Open AccessLong‐term outcomes after perioperative treatment with omega‐3 fatty acid supplements in colorectal cancer
Author(s) -
Sørensen L. Schmidt,
Rasmussen S. Ladefoged,
Calder P. C.,
Yilmaz M. Nytoft,
Schmidt E. Berg,
ThorlaciusUssing O.
Publication year - 2020
Publication title -
bjs open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.974
H-Index - 9
ISSN - 2474-9842
DOI - 10.1002/bjs5.50295
Subject(s) - medicine , perioperative , colorectal cancer , hazard ratio , surgery , gastroenterology , omega 3 fatty acid , incidence (geometry) , cancer , chemotherapy , randomized controlled trial , fatty acid , confidence interval , polyunsaturated fatty acid , docosahexaenoic acid , chemistry , organic chemistry , physics , optics
Background This study aimed to evaluate the effect of perioperative supplementation with omega‐3 fatty acids ( n ‐3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery. Methods Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized to either an n ‐3 FA‐enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control) for 7 days before and after surgery. Outcome measures, including postoperative complications, 3‐year cumulative incidence of local or metastatic colorectal cancer recurrence and 5‐year overall survival, were compared between the groups. Results Of 148 patients enrolled in the study, 125 (65 patients receiving n ‐3 FA‐enriched ONS and 60 receiving standard ONS) were analysed. There were no differences in postoperative complications after surgery ( P = 0·544). The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i. 0·65 to 4·26).The 5‐year survival rate of patients treated with n ‐3 FA was 69·2 (95 per cent c.i. 56·5 to 78·9) per cent, compared with 81·7 (69·3 to 89·4) per cent in the control group ( P = 0·193). After adjustment for age, stage of disease and adjuvant chemotherapy, n ‐3 FA was associated with higher mortality compared with controls (hazard ratio 1·73, 95 per cent c.i. 1·06 to 2·83; P = 0·029). The interaction between n ‐3 FA and adjuvant chemotherapy was not statistically significant. Conclusion Perioperative supplementation with n ‐3 FA did not confer a survival benefit in patients undergoing colorectal cancer surgery. n ‐3 FA did not benefit the subgroup of patients treated with adjuvant chemotherapy or decrease the risk of disease recurrence.